Search hospitals > Texas > Dallas
UT Southwestern/Simmons Cancer Center-Dallas
Claim this profileDallas, Texas 75390
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
688 reported clinical trials
69 medical researchers
Summary
UT Southwestern/Simmons Cancer Center-Dallas is a medical facility located in Dallas, Texas. This center is recognized for care of Brain Tumor, Cancer, Lung Cancer, Leukemia, Lymphoma and other specialties. UT Southwestern/Simmons Cancer Center-Dallas is involved with conducting 688 clinical trials across 641 conditions. There are 69 research doctors associated with this hospital, such as Martha M. Pacheco, David Miller, MD, Matthew Campbell, MD, and Syed M. Kazmi.Area of expertise
1Brain Tumor
Global LeaderStage IV
Stage II
Stage I
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Martha M. PachecoSaint Luke's Cancer Institute - Boise8 years of reported clinical research
Expert in Brain Tumor
Expert in Cancer
37 reported clinical trials
89 drugs studied
David Miller, MDParkland Memorial Hospital3 years of reported clinical research
Studies Ovarian Cancer
Studies Cervical Cancer
21 reported clinical trials
40 drugs studied
Matthew Campbell, MDUT Southwestern/Simmons Cancer Center-Dallas3 years of reported clinical research
Studies Bladder Cancer
Studies Rhabdomyosarcoma
19 reported clinical trials
36 drugs studied
Syed M. KazmiUT Southwestern/Simmons Cancer Center-Dallas8 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
17 reported clinical trials
33 drugs studied
Clinical Trials running at UT Southwestern/Simmons Cancer Center-Dallas
Lung Cancer
Kidney Cancer
Skin Cancer
Prostate Cancer
Esophageal cancer
Brain Tumor
Cancer
Colorectal Cancer
Colon Cancer
Uterine Cancer
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UT Southwestern/Simmons Cancer Center-Dallas?
UT Southwestern/Simmons Cancer Center-Dallas is a medical facility located in Dallas, Texas. This center is recognized for care of Brain Tumor, Cancer, Lung Cancer, Leukemia, Lymphoma and other specialties. UT Southwestern/Simmons Cancer Center-Dallas is involved with conducting 688 clinical trials across 641 conditions. There are 69 research doctors associated with this hospital, such as Martha M. Pacheco, David Miller, MD, Matthew Campbell, MD, and Syed M. Kazmi.
Where is UT Southwestern/Simmons Cancer Center-Dallas located?
The UT Southwestern/Simmons Cancer Center-Dallas is located at 2201 Inwood Rd, Dallas, TX 75390, USA. For detailed directions, please call 214-648-6264.
Who should I call to ask about financial aid or insurance network?
**UT Southwestern/Simmons Cancer Center-Dallas Financial and Insurance Information**
- **Billing and Insurance**: For inquiries, call 469-291-2000 or 866-648-2455. Secure messaging is available via MyChart under the Billing and Inquiries tab, selecting Billing Account Summary. In-person assistance is provided at Clements University Hospital, 6201 Harry Hines Blvd., Dallas, TX 75235, from 7:30 a.m. to 4:00 p.m.
- **Financial Assistance**: Application forms are available in English and Spanish on the UT Southwestern Medical Center website or in person at the William P. Clements Jr. University Hospital Admission Office. For assistance, call 469-291-2000 or 866-648-2455. Submit applications to FinancialAssistance@ UT Southwestern Medical Center, P.O. Box 36423, Dallas, Texas 75235-9662.
- **Financial Aid (Education)**: Contact the Office of Student Financial Aid at 214-648-3611 or via email at financialaid@utsouthwestern.edu. The office is located at M2.200 on South Campus, adjacent to Bryan Williams, M.D. Student Center.
What insurance does UT Southwestern/Simmons Cancer Center-Dallas accept?
UT Southwestern Medical Center, including Simmons Cancer Center-Dallas, accepts most major insurance plans. Not all UT Southwestern faculty providers participate in all plans, so it's recommended to contact the specific clinical practice or hospital to verify acceptance of your plan. For specific information on insurance plans accepted by Simmons Cancer Center-Dallas, contact them directly or visit their website.
What awards or recognition has UT Southwestern/Simmons Cancer Center-Dallas received?
UT Southwestern/Simmons Cancer Center-Dallas, located in Dallas, Texas, is a leading institution in cancer research and care, supported by grants from prestigious organizations including the National Cancer Institute (NCI), Alex’s Lemonade Stand Foundation (ALSF), American Cancer Society (ACS), and the Cancer Prevention Research Institute of Texas (CPRIT). These funds facilitate critical initiatives in breast cancer research, lung cancer screening, tobacco cessation programs, and the advancement of diagnostic and treatment methods through artificial intelligence and digital pathology. Notably, the center has been awarded nearly $19 million in CPRIT funding in 2024 and nearly $15 million in 2023 for its groundbreaking cancer research projects.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.